Amendments to claims:

This listing of claims will replace all prior versions and listing of claims in the application. Please amend claims 1-19 as indicated.

Claim 1 (currently amended): A pharmaceutical composition comprising

4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically acceptable salt thereof (the Agent) and

a water-soluble cellulose ether or an ester of a water-soluble cellulose ether, wherein the composition is such that the Agent component present in a quantity of the composition having 250 mg of the Agent will substantially completely dissolve within 60 minutes in 500 ml of an aqueous medium at a temperature of 37 °C and having a pH of about 1.5.

Claim 2 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1, comprising the Agent and a water-soluble cellulose ether wherein the water-soluble cellulose ether is selected from hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, and a water-soluble salt of carboxymethylcellulose.

Claim 3 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1, comprising the Agent and an ester of a water-soluble cellulose ether wherein the ester of a water-soluble cellulose ether is an ester of hydroxypropyl methylcellulose or hydroxypropyl cellulose which carries one or more ester groups selected from acetate, succinate, phthalate, isophthalate, terephthalate, and trimellitate.

Claim 4 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1, wherein the water-soluble cellulose ether or ester of a water-soluble cellulose ether is selected from hydroxypropyl cellulose, hydroxyethylcellulose, methylcellulose, sodium carboxymethylcellulose, and hydroxypropyl methylcellulose acetate succinate.

Claim 5 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1, comprising the Agent and hydroxypropyl methylcellulose.

Claim 6 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1, wherein the water-soluble cellulose ether is not hydroxypropyl methylcellulose.

Claim 7 (currently amended): A pharmaceutical composition comprising

4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically acceptable salt thereof (the Agent) and

a water-soluble cellulose ether or an ester of a water-soluble cellulose ether, ~~according to claim 1,~~ wherein the composition is such that the Agent component present in a quantity of the composition having 250 mg of the Agent will substantially completely dissolve within 60 minutes in 500 ml of an aqueous medium at a temperature of 37 °C and having a pH of about 1.5 and wherein the weight ratio of the Agent to the water-soluble cellulose ether or ester of a water-soluble cellulose ether is from 40:1 to 2.5:1.

Claim 8 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 or claim 7, further comprising a wetting agent.

Claim 9 (currently amended): The ~~A~~ pharmaceutical composition according to claim 8 wherein the wetting agent is selected from a pharmaceutically acceptable cationic or anionic surfactant.

Claim 10 (currently amended): The ~~A~~ pharmaceutical composition according to claim 8 wherein the wetting agent is an alkali metal (8-20C)alkyl sulphate.

Claim 11 (currently amended): The ~~A~~ pharmaceutical composition according to claim 1 or claim 7, further comprising ~~the Agent, a water-soluble cellulose ether or ester of a water-soluble cellulose ether,~~ a wetting agent~~,~~ and one or more fillers, binders, disintegrants~~,~~ or

lubricants.

Claim 12 (currently amended): A pharmaceutical composition comprising:

(a) from 10 to 80 parts of 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically acceptable salt thereof (the Agent);

(b) from 0.05 to 5 parts anionic surfactant;

(c) from 10 to 60 parts of one or more fillers selected from lactose, mannitol, and microcrystalline cellulose;

(d) from 1 to 10 parts of one or more disintegrants selected from carboxymethylcellulose sodium, carboxymethylcellulose calcium, croscarmellose sodium, crospovidone, and sodium starch glycolate;

(e) from 1 to 20 parts of a binder selected from a polyvinylpyrrolidone and hydroxypropyl methylcellulose; and

(f) 0 to 3 parts of a lubricant;

wherein all parts are by weight and the sum of the parts (a)+(b)+(c)+(d)+(e)+(f)=100, and at least one of the components selected from (d) or (e) contains a water-soluble cellulose ether selected from hydroxypropyl methylcellulose and carboxymethylcellulose sodium,
wherein the composition is such that the Agent component present in a quantity of the composition having 250 mg of the Agent will substantially completely dissolve within 60 minutes in 500 ml of an aqueous medium at a temperature of 37 °C and having a pH of about 1.5.

Claim 13 (currently amended): The ~~A~~ pharmaceutical composition according to any one of claims ~~claim~~ 1, 7 and 12, which is a solid pharmaceutical composition adapted for oral administration.

Claim 14 (currently amended): A solid pharmaceutical composition comprising:

(i) a core comprising 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline or a pharmaceutically acceptable salt thereof (the Agent); and

(ii) a coating comprising an ester of a water-soluble cellulose ether or a water-soluble cellulose ether,

wherein the composition is such that the Agent component present in a quantity of the composition having 250 mg of the Agent will substantially completely dissolve within 60 minutes in 500 ml of an aqueous medium at a temperature of 37 °C and having a pH of about 1.5.

Claim 15 (currently amended): The ~~A~~ solid pharmaceutical composition according to claim 14 which is a tablet, pellet, or granule adapted for oral administration, comprising a core coated with a film coating wherein:

the core comprises:

from 45 to 55% of the Agent;

from 25 to 40% lactose;

from 5 to 15% microcrystalline cellulose;

from 2 to 6% disintegrant;

from 1 to 5% povidone;

from 0.05 to 1% sodium dodecyl sulphate; and

from 0.1 to 4% lubricant;

and wherein the film coating comprises:

from 0.5 to 3% water-soluble cellulose ether;

from 0 to 0.5% plasticiser;

from 0 to 0.5% dispersion aid;

from 0 to 0.5% opacifier; and

from 0 to 0.5% colorant;

wherein all % are by weight based upon the total weight of the composition.

Claim 16 (currently amended): The ~~A~~ pharmaceutical composition according to any one of claims ~~claim~~ 1, 7 and 12 wherein the Agent is 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline.

Claim 17 (currently amended): A method of preparing a pharmaceutical composition which comprises, admixing 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)-quinazoline or a pharmaceutically acceptable salt thereof (the Agent) with a water-soluble cellulose ether and/or or ester of a water-soluble cellulose ether, wherein the composition is such that the Agent component present in a quantity of the composition having 250 mg of the Agent will substantially completely dissolve within 60 minutes in 500 ml of an aqueous medium at a temperature of 37 °C and having a pH of about 1.5.

Claim 18 (currently amended): A method for inhibiting the rate of precipitation of the Agent from solution in the GI tract of a patient in need of the Agent, comprising orally administering to said patient a composition according to any one of claims ~~claim~~ 1, 7 and 12.

Claim 19 (currently amended): A method for reducing inter-patient variability in bioavailability and/or plasma concentrations of the Agent in a patient in need of the Agent, comprising orally administering to said patient a pharmaceutical composition according to any one of claims ~~claim~~ 1, 7 and 12.